Wilson Therapeutics’ 2017 Annual Report published
Apr 27, 2018
As of today, the 2017 Annual Report of Wilson Therapeutics AB (publ) is available as a pdf file on the company’s website www.wilsontherapeutics.com.
Printed copies can be ordered by post to Wilson Therapeutics AB (publ), Kungsgatan 3, SE-111 43 Stockholm, Sweden, by telephone +46 (0) 8 796 00 00 or by e-mail to lisa.andersson@wtx.se.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information please contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
| Phone: | +46 8 796 00 00 |
| E-mail: | jonas.hansson@wtx.se |
Lauren Williams, Head of Investor Relations, Wilson Therapeutics AB
| Phone: | +44 7958 669 896 |
| E-mail: | lauren.williams@wtx.se |
Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
Kungsgatan 3
SE-111 43 Stockholm
This information is information that Wilson Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 07:00 CET on April 27, 2018.
